NOSIUM (NOSIUM ) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
6 Jun, 2025Executive summary
Revenue declined sharply year-over-year, with significant cost reductions and asset write-downs impacting results.
Focus remained on completing the reverse acquisition of Brasserie Gruppen and divesting non-core holdings.
The company proactively wrote down assets by approximately SEK 10 million each at the parent and group level.
Financial highlights
Q4 group revenue was SEK 1,430k (down 63% YoY); full-year group revenue SEK 7,148k (down 62% YoY).
Q4 group operating result was SEK -1,363k (improved from -3,976k YoY); full-year SEK -7,393k (from -8,057k YoY).
Q4 group net result attributable to parent shareholders was SEK -11,576k (from -15,874k YoY); full-year SEK -23,117k (from -22,444k YoY).
Q4 parent company net result was SEK -10,951k (from 1,905k YoY); full-year SEK -19,932k (from -752k YoY).
Cash flow from operations improved to SEK -814k in Q4 (from -3,829k YoY); full-year SEK -8,431k (from -9,564k YoY).
Outlook and guidance
Management remains committed to completing the Brasserie Gruppen acquisition and expects it to create new growth opportunities.
Continued focus on cost control, divestment of non-core assets, and strengthening the financial position.
No dividend proposed for 2024.
Latest events from NOSIUM
- 2025 saw declining revenue and losses amid a strategic shift to medtech via the Medicortex merger.NOSIUM
Q4 202520 Feb 2026 - Positive Q3 results and a transformative medtech acquisition mark a pivotal quarter.NOSIUM
Q3 202527 Nov 2025 - Cost reductions and divestments improved results amid ongoing strategic transformation.NOSIUM
Q2 202528 Aug 2025 - Sharp revenue decline and major restructuring, including a reverse acquisition and share issue.NOSIUM
Q3 202413 Jun 2025 - Sharp revenue drop offset by improved equity and new capital; cost cuts and divestments ongoing.NOSIUM
Q2 202413 Jun 2025 - Operating losses narrowed and cost base improved as NOSIUM targets new structural deals.NOSIUM
Q1 20256 Jun 2025